Page 10 - Commercial Launch News Today : Breaking News, Live Updates & Top Stories | Vimarsana

- Cash, cash equivalents, and investments of $423 million at December 31, 2020 - Victoria, BC, March 3, 2021--(T-Net)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) today issued its financial results for the fourth quarter and year ended December 31, 2020. Amounts, unless specified otherwise, are expressed in U.S. dollars. "Over the past year, Aurinia matured into a fully-integrated biopharmaceutical company with capabilities spanning R&D, clinical, regulatory, CMC, and commercial. The recent FDA approval and immediate launch of LUPKYNIS underscores the exemplary performance and ex...

Aurinia Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Operational Highlights LUPKYNIS TM is the first FDA-approved oral therapy for lupus nephritis a condition that causes irreversible kidney damage and increases the risk of kidney failure, cardiac events, and death – – Cash, cash equivalents, and investments of $423 million at December 31, 2020 – – Conference call to be hosted today at 4:30 p.m. ET – Aurinia Pharmaceuticals Inc. today issued its financial results for the fourth quarter … – LUPKYNIS TM is the first FDA-approved oral therapy for lup...

KPMG, BitGo, Coin Metrics Joins Hands to Unveil New Crypto Suite for Institutional Adoption Feb 19 2021 · 11:47 UTC | Updated Feb 19 2021 · 11:54 by Bhushan Akolkar · 2 min read Photo: Depositphotos You have successfully joined our subscriber list. The combined suite of products aims to provide services like risk management, compliance, and control patterns with crypto investments thereby providing a boost to institutional adoption. On Thursday, February 18, KPMG, BitGo and Coin Metrics joined hands for a new project with the aim of boosting institutional crypto adoption. This combined...